# Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

> **NCT07082842** · PHASE3 · RECRUITING · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 472 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** HEC585
- **DRUG:** Placebo
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT07082842
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2031-01-15
- **Final completion:** 2032-02-15
- **Target enrollment:** 472 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082842, "Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07082842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*